Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Bio-Techne Corp TECH

Healthcare  —  Biotechnology
72.61 0.04 0.06% as of 25 Sep
Market cap
$11.4B
P/E
62.1×
S&P 500 Member Dividend Champion (3y)
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Bio-Techne Corp (TECH) Business Profile

Updated before January 2025

Company Overview

Bio-Techne Corporation (NASDAQ: TECH) is a leading global life sciences company that specializes in providing innovative tools and solutions for the research, diagnostics, and biopharmaceutical manufacturing sectors. Founded in 1976 and headquartered in Minneapolis, Minnesota, Bio-Techne has grown into a prominent player in the biotechnology industry. The company was initially established as R&D Systems, focusing on the development of high-quality proteins and antibodies. Over the years, it has expanded its portfolio through strategic acquisitions and organic growth, rebranding as Bio-Techne in 2014 to reflect its broader scope of operations.

The company is led by a seasoned executive team, with Chuck Kummeth serving as the President and Chief Executive Officer. Under his leadership, Bio-Techne has pursued an aggressive growth strategy, emphasizing innovation, operational excellence, and market expansion. The company operates globally, with a presence in North America, Europe, and Asia, and employs over 2,500 professionals dedicated to advancing life sciences research and healthcare solutions.

Core Business Segments

Bio-Techne operates through three primary business segments, each catering to distinct aspects of the life sciences and healthcare industries:

1. Protein Sciences

This segment is the cornerstone of Bio-Techne’s operations, offering a comprehensive range of high-quality proteins, antibodies, and related reagents. Key products include:

  • Recombinant Proteins: Essential for cell culture, drug development, and research applications.
  • Antibodies: High-specificity antibodies used in diagnostics and therapeutic research.
  • ELISA Kits: Enzyme-linked immunosorbent assay kits for detecting and quantifying proteins.
  • Small Molecules and Inhibitors: Tools for studying cellular pathways and mechanisms.

2. Diagnostics and Genomics

This segment focuses on providing diagnostic tools and genomic solutions for clinical and research applications. Key offerings include:

  • Molecular Diagnostics: Products for detecting genetic mutations and biomarkers.
  • Genomic Analysis Tools: Instruments and reagents for next-generation sequencing and gene expression studies.
  • Clinical Assays: Diagnostic kits for disease detection and monitoring.

3. Cell and Gene Therapy

Bio-Techne is a significant player in the rapidly growing cell and gene therapy market. This segment provides critical tools and services for the development and manufacturing of advanced therapies. Key products include:

  • Cell Culture Media: Optimized solutions for growing and maintaining cells.
  • Gene Editing Tools: CRISPR and other technologies for genetic modification.
  • Custom Manufacturing Services: Tailored solutions for biopharmaceutical companies.

Business Model

Bio-Techne’s business model is centered on innovation, integration, and customer-centricity. The company generates revenue through the sale of products, services, and licensing agreements. Its approach includes:

  • Research and Development: Investing heavily in R&D to develop cutting-edge products and technologies.
  • Strategic Acquisitions: Expanding its portfolio and market reach through acquisitions of complementary businesses.
  • Global Distribution Network: Leveraging a robust distribution network to serve customers worldwide.
  • Customer Support: Providing exceptional technical support and training to ensure customer success.

Strategic Direction

Bio-Techne is committed to driving growth and innovation in the life sciences industry. Key strategic priorities include:

  • Expanding Product Portfolio: Developing new products and technologies to address emerging market needs.
  • Sustainability Goals: Implementing environmentally friendly practices in manufacturing and operations.
  • Geographic Expansion: Strengthening its presence in high-growth markets, particularly in Asia-Pacific.
  • Digital Transformation: Leveraging digital tools and platforms to enhance customer engagement and operational efficiency.

Competitive Landscape

Bio-Techne operates in a highly competitive industry, facing competition from both established players and emerging startups. Key competitors include:

  • Thermo Fisher Scientific: A global leader in life sciences tools and diagnostics.
  • Danaher Corporation: Known for its diverse portfolio of life sciences and diagnostics products.
  • Sartorius AG: Specializes in bioprocess solutions and laboratory products.
  • Abcam: Focused on providing high-quality antibodies and reagents.

Despite the competition, Bio-Techne differentiates itself through its comprehensive product portfolio, strong customer relationships, and commitment to innovation.

Risk Factors

Like any business, Bio-Techne faces several risks that could impact its operations and financial performance. Key risks include:

  • Market Dependence: Reliance on the life sciences and healthcare markets, which are subject to economic and regulatory fluctuations.
  • Supply Chain Disruptions: Potential disruptions in the supply of raw materials and components.
  • Technological Obsolescence: The risk of products becoming outdated due to rapid advancements in technology.
  • Regulatory Compliance: Navigating complex and evolving regulatory requirements in different regions.

Recent Developments

Bio-Techne has been actively pursuing growth opportunities and enhancing its product offerings. Recent developments include:

  • Launch of New Products: Introduction of innovative tools for cell and gene therapy research.
  • Strategic Partnerships: Collaborations with leading biopharmaceutical companies to advance therapeutic development.
  • Sustainability Initiatives: Implementation of eco-friendly practices in manufacturing and packaging.
  • Global Expansion: Establishment of new facilities and offices in key markets.

Investment Considerations

Investors considering Bio-Techne should weigh the following strengths and risks:

Strengths:

  • Diverse product portfolio catering to multiple market segments.
  • Strong track record of innovation and growth.
  • Robust financial performance and profitability.
  • Global presence and established customer base.

Risks:

  • Exposure to market and regulatory uncertainties.
  • Dependence on key customers and suppliers.
  • Intense competition in the life sciences industry.

Conclusion

Bio-Techne Corporation is a dynamic and innovative company that plays a critical role in advancing life sciences research and healthcare solutions. With a strong market position, diverse product portfolio, and commitment to sustainability, the company is well-positioned for future growth. However, investors should carefully consider the associated risks before making investment decisions.